ACADIA PHARMACEUTICALS INC. (ACAD) FY2026 Q2 Balance Sheet

Income StatementCash FlowBalance Sheet

Balance Sheet

As of 2026-06-30

Swipe to see the full flow
ACADIA PHARMACEUTICALS INC. (ACAD) FY2026 Q2 Balance SheetBalance sheet as of 2026-06-30. The chart shows assets, liabilities and equity at that date.Current liabilities$361.44 MLiabilities$436.29 MCurrent assets$1.22 BNon-current liabilities$74.86 MEquity$1.31 BAssets$1.74 BGross equity(calculated)$3.09 BNon-current assets$518.36 MHOLDINGSASSET CLASSASSETSCLAIM CLASSCLAIM SUB-CLASSCLAIMSInvestment securities, available-for-saleCash and cash equivalentsAccounts receivable, netPrepaid expenses and other current assetsInventoryInterest and other receivablesDeferred tax assetsIntangible assets, netLong-term inventoryOperating lease right-of-use assetsProperty and equipment, netRestricted cashOther assetsAccrued liabilitiesAccounts payableOperating lease liabilitiesOther long-term liabilitiesAdditional paid-in capitalCommon stock, $0.0001 par value; 225,000,000 shares authorized at June 30, 2026 and December 31, 2025; 172,132,442 shares and 170,309,376 shares issued and outstanding at June 30, 2026 and December 31, 2025, respectivelyCurrent assetsNon-current assetsAssetsCurrent liabilitiesNon-current liabilitiesLiabilitiesEquityGross equity (calculated)Accumulated deficitAccumulated other comprehensive (loss) incomeCurrent liabilitiesCurrent liabilities$361.44 MAccrued liabilitiesAccrued liabilities$316.87 MLiabilitiesLiabilities$436.29 MAccounts payableAccounts payable$44.57 MCurrent assetsCurrent assets$1.22 BInvestment securities, available-for-saleInvestment securities, available-for-sale$571.49 MOperating lease liabilitiesOperating lease liabilities$59.55 MNon-current liabilitiesNon-current liabilities$74.86 MEquityEquity$1.31 BOther long-term liabilitiesOther long-term liabilities$15.31 MCash and cash equivalentsCash and cash equivalents$384.99 MAssetsAssets$1.74 BGross equity (calculated)Gross equity(calculated)$3.09 BAccounts receivable, netAccounts receivable, net$150.64 MPrepaid expenses and other current assetsPrepaid expenses and other current assets$69.37 MInventoryInventory$32.37 MInterest and other receivablesInterest and other receivables$15.69 MDeferred tax assetsDeferred tax assets$240.68 MIntangible assets, netIntangible assets, net$103.45 MNon-current assetsNon-current assets$518.36 MAdditional paid-in capitalAdditional paid-in capital$3.09 BLong-term inventoryLong-term inventory$76.30 MOperating lease right-of-use assetsOperating lease right-of-use assets$69.42 MProperty and equipment, netProperty and equipment, net$17.11 MRestricted cashRestricted cash$7.85 MOther assetsOther assets$3.55 MCommon stock, $0.0001 par value; 225,000,000 shares authorized at June 30, 2026 and December 31, 2025; 172,132,442 shares and 170,309,376 shares issued and outstanding at June 30, 2026 and December 31, 2025, respectivelyCommon stock$16.00 KAccumulated deficitAccumulated deficit−$1.78 BAccumulated other comprehensive (loss) incomeAccumulated other comprehensive (loss) income−$958.00 K
Chart details

ACADIA PHARMACEUTICALS INC. (ACAD) FY2026 Q2 Balance Sheet

Balance sheet as of 2026-06-30. The chart shows assets, liabilities and equity at that date.

Assets
1,742,900,000 US dollars
Current assets
1,224,545,000 US dollars
Non-current assets
518,355,000 US dollars
Liabilities
436,291,000 US dollars
Current liabilities
361,436,000 US dollars
Non-current liabilities
74,855,000 US dollars
Equity
1,306,609,000 US dollars
Investment securities, available-for-sale
571,489,000 US dollars
Cash and cash equivalents
384,985,000 US dollars
Accounts receivable, net
150,642,000 US dollars
Prepaid expenses and other current assets
69,369,000 US dollars
Inventory
32,372,000 US dollars
Interest and other receivables
15,688,000 US dollars
Deferred tax assets
240,679,000 US dollars
Intangible assets, net
103,448,000 US dollars
Long-term inventory
76,301,000 US dollars
Operating lease right-of-use assets
69,424,000 US dollars
Property and equipment, net
17,107,000 US dollars
Restricted cash
7,846,000 US dollars
Other assets
3,550,000 US dollars
Accrued liabilities
316,870,000 US dollars
Accounts payable
44,566,000 US dollars
Operating lease liabilities
59,547,000 US dollars
Other long-term liabilities
15,308,000 US dollars
Additional paid-in capital
3,085,800,000 US dollars
Common stock, $0.0001 par value; 225,000,000 shares authorized at June 30, 2026 and December 31, 2025; 172,132,442 shares and 170,309,376 shares issued and outstanding at June 30, 2026 and December 31, 2025, respectively
16,000 US dollars
Preferred stock, $0.0001 par value; 5,000,000 shares authorized at June 30, 2026 and December 31, 2025; no shares issued and outstanding at June 30, 2026 and December 31, 2025
0 US dollars
Accumulated deficit
negative 1,778,249,000 US dollars
Accumulated other comprehensive (loss) income
negative 958,000 US dollars
Gross equity (calculated)
3,085,816,000 US dollars. Net equity plus the magnitudes of its negative contributions equals gross positive equity. The negative contributions enter this reconciliation as add-backs; their filed signs stay negative.

Chart connections

  • Assets equal liabilities plus consolidated equity. Consolidated equity includes noncontrolling interests when reported.
  • Treasury shares and other negative equity contributions reduce equity.
ACADIA PHARMACEUTICALS INC. (ACAD) FY2026 Q2 Balance Sheet Sankey chart
Free to share unchanged, with credit to Plicit.ai · CC BY-NC-ND 4.0Download PNG

Newsletter

Get the teardowns by email

Subscribe if you want the public-company teardowns in your inbox when they're released.

Product waitlist

Health Check and Teardown for your own company

A health check uncovers insights of your private books, not a public ticker. Join this list to get notified as soon as we go-live!